Seeks nod from DCGI for phase 2/3 trial of Covaxin, among 2-to-17 age group
A student is vaccinated against COVID-19, at a govt school, in Jalandhar, Punjab, on Monday. Pic/ANI
Bharat Biotech has sought permission from Drugs Controller General of India (DCGI) to conduct a phase 2/3 study of its anti-COVID vaccine Covaxin as a booster dose among those aged two to 17 years, sources told PTI.
Presently, precaution dose of Covaxin and Covishield is administered to all those aged 18 and above, and have completed nine months after the second dose.
ADVERTISEMENT
The Hyderabad-based company submitted the application for the trial to the DCGI on April 29. The study is likely to be conducted in six sites, including Delhi (at AIIMS) and Patna.
Kerala reports 29 deaths in 24 hours, nationwide tally is 31
India reported 3,205 fresh novel Coronavirus infections in a day, pushing the number of active cases to 19,509 and the overall tally to 4,30,88,118, according to the Union Health Ministry data updated Wednesday.
The data released at 8 am also showed that 31 fatalities from COVID—29 of them from Kerala alone—were reported in a 24-hour span, taking the cumulative death toll to 5,23,920. An increase of 372 cases has been recorded in the active COVID-19 caseload which now stand at 19,509.
4,30,88,118 Total no. of Coronavirus cases in india so far
5,23,920 Total no. of deaths due to the virus in India so far
19,509 Total no. of active cases in India
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
Subscribe today by clicking the link and stay updated with the latest news!" Click here!
